The aim of this trial is to find out how safe and tolerable the drug efgartigimod administered intravenously (IV) is in pediatric participants from 2 to less than 18 years of age with generalized myasthenia gravis (gMG).
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
James Howard
Neurology
Clinical or Medical
Interventional
Brain, Head, Nervous System
22-0878
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
